Abstract 2954 3′-end stabilization increases cellular half-life and improves potency of mRNA therapeutics
Effective mRNA therapeutics often depend on high protein output per delivered mRNA molecule, which requires maximizing the stability of the therapeutic mRNA in the cytoplasm. While deadenylation is often rate-limiting for endogenous mRNA decay, it is not known what process determines the mRNA half-life for therapeutic mRNAs, which undergo sequence optimization, are not spliced, typically include modified uridines, and enter the cytoplasm through a pathway that differs from endogenous mRNA export.
Authors
- Brian R. Fritz
- Groves Dixon (ORCID: https://orcid.org/0000-0001-5501-6024)
- Joshua T. Zimmer (ORCID: https://orcid.org/0000-0002-6438-2277)
- Alicia A. Bicknell (ORCID: https://orcid.org/0009-0002-8552-1624)
- David W. Reid (ORCID: https://orcid.org/0000-0001-9517-8212)
- Eckhard Jankowsky (ORCID: https://orcid.org/0000-0001-7677-7412)
- Juliana C.N. Chan (ORCID: https://orcid.org/0000-0003-1325-1194)
- Marissa C. Licata
- Valerie Taruno
Institutions
- University of Michigan (US)
Publication Details
- Journal
- Journal of Biological Chemistry
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1016/j.jbc.2025.109792
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- National Institutes of Health